Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Starting soon · Phase 2

Conditions studied: Breast Cancer

In brief

This study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer. Based on metabolic response after two cycles, patients receive either intenstified treatment (Arm A) or de-escalation treatment (Arm B), alongside with a concurrent standard-treatment control group (Arm C). The study aims to establish a response-adaptive, imaging-guided treatment paradigm to optimize neoadjuvant therapy in HER2-positive breast cancer.

Key facts

Study ID

NCT07527806

Run by

Peking University Cancer Hospital & Institute

People needed

156

Starts

2026-05-01

Expected to finish

2029-12-31

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntary participation with written informed consent obtained prior to any study-related procedures
• Age ≥ 18 years, male or female.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
• Histologically confirmed HER2-positive (IHC 3+, or IHC 2+ with ISH amplification) stage I-III (cT1-3/cN0-2) breast cancer
• Tumor diameter ≥ 1.5 cm assessed by imaging, with at least one PET-evaluable lesion present
• Patient must have known estrogen receptor (ER) and progesterone receptor (PR) status. For Arm B, ER expression ≥ 10% and must be strongly positive.
• Adequate bone marrow, liver, and renal function: WBC > 3.0 × 10⁹/L, ANC ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 10.0 g/dL; total bilirubin ≤ ULN (excluding Gilbert's syndrome), ALP ≤ 2.5 × ULN, AST/ALT ≤ 1.5 × ULN; creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min.
• Patients who participate in the trial have good compliance and are willing to comply with the follow-up visit.

You may not qualify if…

• Prior treatment with any chemotherapy, anti-HER2 therapy, radiotherapy, or endocrine therapy, etc
• Locally advanced (cT4/cN3) or bilateral breast cancer
• Patients with known allergies to any active ingredients or excipients of investigational medicinal product
• Other malignancy diagnosed within 5 years prior to enrollment, excluding cervical carcinoma in situ and cured melanoma skin cancer
• Left ventricular ejection fraction (LVEF) < 55%
• Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg)
• Severely cardiovascular disease
• Current known infection with HIV, hepatitis B virus, or hepatitis C virus
• Patients with pulmonary disease requiring continuous oxygen therapy, previous history of bleeding diathesis or patient is currently receiving anti-coagulant therapy, or immunosuppressive agent
• Major surgical procedure or significant traumatic injury
• Patient has other concurrent severe and/or uncontrolled medical conditions.
• Concurrent participation in other interventional clinical trial
• History of receiving any investigational treatment within 28 days prior to randomization
• Pregnant or breast-feeding women or patients not willing to apply highly effective contraception as defined in the protocol
• Inability to lie flat or presence of psychiatric disorders such as claustrophobia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.